Cumberland Pharmaceuticals Expands Vibativ Availability for Care
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is making significant strides in enhancing patient care with the introduction of the new Vibativ® 4-Vial Starter Pak. This exciting development follows Cumberland's recent contract with Vizient®, a leader in healthcare performance improvement.
Increased Access Through Vizient
Vizient plays a crucial role in the healthcare landscape, serving over 65% of acute care providers across the country, including 97% of academic medical centers. The partnership between Vizient and Cumberland Pharmaceuticals aims to ensure that healthcare providers across various acuity levels can access Vibativ more efficiently.
About the Vibativ 4-Vial Starter Pak
The Vibativ 4-Vial Starter Pak is designed to support flexible treatment initiation for patients requiring antibiotic therapy in both inpatient and outpatient settings. The availability of this 4-vial configuration is expected to optimize the treatment process, particularly for life-threatening infections.
CEO's Statement
A.J. Kazimi, CEO of Cumberland Pharmaceuticals, expressed enthusiasm about this development. He stated, "We're pleased to expand availability of the new Vibativ 4-Vial Starter Pak for Vizient-contracted providers, supporting the cost-efficient delivery of our potent antibiotic in hospitals, infusion centers and outpatient centers nationwide." This statement emphasizes the company's commitment to providing healthcare professionals with the necessary tools to deliver effective patient care.
What Is Vibativ?
Vibativ (telavancin) is an FDA-approved injectable antibiotic indicated for treating serious bacterial infections such as hospital-acquired pneumonia and complicated skin infections. Its unique mechanism of action allows it to effectively combat Gram-positive pathogens, including challenging strains like MRSA.
Clinical Efficacy
The efficacy of Vibativ has been well-demonstrated. It provides bactericidal activity within six hours and reaches targeted infection sites efficiently. Vibativ has been shown to have higher cure rates compared to standard treatments, making it an essential option in the pharmaceutical arsenal against resistant infections.
Broader Availability and Future Potential
In addition to the new 4-vial option, this innovative antibiotic is also available in a 12-vial carton format to further accommodate healthcare providers via various distribution channels. Cumberland Pharmaceuticals remains dedicated to improving access for its products to ensure better health outcomes for patients.
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals is a pioneering biopharmaceutical company based in the United States, focused on developing and commercializing innovative products to improve patient care. Their diverse range of FDA-approved brands includes Acetadote®, Caldolor®, Kristalose®, Sancuso®, Vaprisol®, and Vibativ®. This well-rounded portfolio reflects the company's commitment to addressing a wide array of medical needs in acute care and specialty markets.
Ongoing Research and Development
The company is not only enhancing its product offerings but is also heavily invested in research, including ongoing Phase II studies for its ifetroban product candidate. This research aims to tackle conditions such as Duchenne muscular dystrophy and idiopathic pulmonary fibrosis, furthering its mission to address unmet medical needs.
Frequently Asked Questions
What is the Vibativ 4-Vial Starter Pak?
The Vibativ 4-Vial Starter Pak is a compact packaging option allowing healthcare providers to initiate treatment more flexibly for patients requiring this antibiotic therapy.
How does Vibativ work?
Vibativ works by targeting Gram-positive bacteria, including difficult strains like MRSA, offering physician a powerful option for treating serious infections.
Who benefits from Cumberland's contract with Vizient?
Healthcare providers contracted with Vizient, including hospitals and outpatient centers, will benefit from enhanced access to Vibativ, improving patient care delivery.
What other products does Cumberland Pharmaceuticals offer?
Cumberland Pharmaceuticals offers a range of products including Acetadote, Caldolor, and Sancuso, targeting various healthcare needs in their market segments.
What are the ongoing research initiatives by Cumberland Pharmaceuticals?
The company is pursuing Phase II studies for its ifetroban candidate, focusing on treating conditions such as Duchenne muscular dystrophy and lung-related diseases.
